However, immune oncology presents unique challenges from an imaging standpoint, prominently including the possibility of pseudo-progression.
TORONTO, Oct. 14, 2021 /PRNewswire-PRWeb/ -- A large majority of the work being done in oncology drug development relates in one way or another to manipulation of the immune system. This approach has many benefits for patients, including the promise of a more robust and long-lasting response to therapy combined with more tolerable side-effect profiles relative to traditional chemotherapy or targeted therapies. However, immune oncology presents unique challenges from an imaging standpoint, prominently including the possibility of pseudo-progression.
This talk will review the history of immunotherapy, discuss a range of approaches currently in the clinic or in development and explore the unique challenges that these new treatment options present in the clinical trials setting.
This webinar is Part 2 of a series on Imaging in Oncology:
Click here for Part 1: Advanced Imaging in Oncology (upcoming on Nov 2/21)
Click here for Part 3: Deep Learning for Image Analysis (upcoming on Nov 8/21)
For more information, or to register for this event, visit Assessing Imaging Outcomes in Immune Oncology.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, firstname.lastname@example.org